4592 — SanBio Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.15 | ||
| Price to Tang. Book | 6.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.67% | ||
| Return on Equity | -55.87% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jan | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | n/a | n/a | n/a | n/a | n/a | 1,779 | 2,833 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
Directors
- Toru Kawanishi CHM (51)
- Keita Mori PRE (54)
- Akihiro Tsujimura VPR (53)
- Yoshihiro Sumiya EXO
- Chris Horan EXO
- Bijan Nejadnik EXO
- Naoki Tsukahara EXO
- Hiroshi Yamamoto EXO (40)
- Noboru Kotani IND (64)
- Last Annual
- January 31st, 2026
- Last Interim
- July 31st, 2026
- Incorporated
- February 27th, 2013
- Public Since
- April 8th, 2015
- No. of Shareholders
- 50,267
- No. of Employees
- 33
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 78,058,343
- Address
- 13F, St. Luke Tower, 8-1, Akashi-cho, CHUO-KU, 104-0044
- Web
- https://www.sanbio.com/
- Phone
- +81 362643481
- Auditors
- Deloitte Touche Tohmatsu LLC
Latest News for 4592
Upcoming Events for 4592
Q3 2027 SanBio Co Ltd Earnings Release
Dividend For 4592.T - 0.0000 JPY
Full Year 2027 SanBio Co Ltd Earnings Release
Similar to 4592
3-D Matrix
Tokyo Stock Exchange
ADR Biomedical Holdings
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
FAQ
As of Today at 05:07 UTC, shares in SanBio are trading at ¥924. This share price information is delayed by 15 minutes.
Shares in SanBio last closed at ¥924 and the price had moved by -66.47% over the past 365 days. In terms of relative price strength the SanBio share price has underperformed the Nikkei 225 Index by -73.99% over the past year.
The overall consensus recommendation for SanBio is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSanBio does not currently pay a dividend.
SanBio does not currently pay a dividend.
SanBio does not currently pay a dividend.
To buy shares in SanBio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥924, shares in SanBio had a market capitalisation of ¥72bn.
Here are the trading details for SanBio:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4592
Based on an overall assessment of its quality, value and momentum SanBio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in SanBio is ¥1,400. That is 51.52% above the last closing price of ¥924.
Analysts covering SanBio currently have a consensus Earnings Per Share (EPS) forecast of -¥52 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SanBio. Over the past six months, its share price has underperformed the Nikkei 225 Index by -56.43%.
As of the last closing price of ¥924, shares in SanBio were trading -37.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The SanBio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥924.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
SanBio's management team is headed by:
- Toru Kawanishi - CHM
- Keita Mori - PRE
- Akihiro Tsujimura - VPR
- Yoshihiro Sumiya - EXO
- Chris Horan - EXO
- Bijan Nejadnik - EXO
- Naoki Tsukahara - EXO
- Hiroshi Yamamoto - EXO
- Noboru Kotani - IND